Furthermore, the efficiency of multiple peptide‐based cancer vaccine involving IGF2BP3 peptide has been investigated by a phase II clinical trial in patients with head and neck squamous cell carcinoma, which revealed a relationship between the immune response induced by this vaccine and better prognosis.46 The gene discussed is IGF2BP3; the disease is head and neck squamous cell carcinoma.